Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells

Biochemical Pharmacology

Volumn 79, Issue 5, 2010, Pages 777-783

  Räikkönen, Johanna ^a   Mönkkönen, Hannu ^a   Auriola, Seppo ^a   Mönkkönen, Jukka ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A; Bisphosphonate induced ATP analog; Isopentenyl pyrophosphate; Isoprenoid; Mevalonate pathway; Zoledronic acid

Indexed keywords

ADENOSINE TRIPHOSPHATE DERIVATIVE; AMINO ACID TRANSFER RNA LIGASE; CELL PROTEIN; FARNESOL; GERANYL PYROPHOSPHATE; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOPENTENYL DIPHOSPHATE; ISOPENTENYL DIPHOSPHATE DELTA ISOMERASE; MEVALONIC ACID; PROTEIN RAP1A; TERPENOID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PRENYLATION; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIPHOSPHONATES; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; FARNESOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMITERPENES; HUMANS; IMIDAZOLES; MEVALONIC ACID; ORGANOPHOSPHORUS COMPOUNDS;

EID: 71849102718     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.10.003     Document Type: Article

References (44)

1. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
2. Amin D., Cornell S.A., Gustafson S.K., Needle S.J., Ullrich J.W., Bilder G.E., et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33 (1992) 1657-1663
3. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 359 (2002) 2018-2026
4. Diel I.J., Solomayer E.F., and Bastert G. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 88 (2000) 3080-3088
5. Roux C., and Dougados M. Treatment of patients with Paget's disease of bone. Drugs 58 (1999) 823-830
6. Coleman R.E. The role of bisphosphonates in breast cancer. Breast 13 Suppl. 1 (2004) S19-S28
7. Goffinet M., Thoulouzan M., Pradines A., Lajoie-Mazenc I., Weinbaum C., Faye J.C., et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6 (2006) 60
8. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami H.A., and Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84 (2001) 1126-1134
9. Shipman C.M., Rogers M.J., Apperley J.F., Russell R.G., and Croucher P.I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98 (1997) 665-672
10. Kubista B., Trieb K., Sevelda F., Toma C., Arrich F., Heffeter P., et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 24 (2006) 1145-1152
11. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360 (2009) 679-691
12. Buhaescu I., and Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40 (2007) 575-584
13. van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264 (1999) 108-111
14. Rondeau J.M., Bitsch F., Bourgier E., Geiser M., Hemmig R., Kroemer M., et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 1 (2006) 267-273
15. Benford H.L., Frith J.C., Auriola S., Mönkkönen J., and Rogers M.J. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56 (1999) 131-140
16. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 (1998) 581-589
17. Mönkkönen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsäläinen J., et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 147 (2006) 437-445
18. Mönkkönen H., Kuokkanen J., Holen I., Evans A., Lefley D., Jauhiainen M., et al. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 19 (2008) 391-399
19. Räikkönen J., Crockett J.C., Rogers M.J., Mönkkönen H., Auriola S., and Mönkkönen J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 157 (2009) 427-435
20. Mitrofan L., Pelkonen J., and Mönkkönen J. The level of ATP analogue and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. Bone (2009) 10.1016/j.bone.2009.08.010
21. Mönkkönen H., Ottewell P.D., Kuokkanen J., Mönkkönen J., Auriola S., and Holen I. Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci 81 (2007) 1066-1070
22. Jauhiainen M., Mönkkönen H., Räikkönen J., Mönkkönen J., and Auriola S. Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B: Anal Technol Biomed Life Sci 877 (2009) 2967-2975
23. Rogers M.J., Brown R.J., Hodkin V., Blackburn G.M., Russell R.G., and Watts D.J. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 224 (1996) 863-869
24. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., Ylitalo K.V., Mönkkönen J., Rogers M.J., et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61 (2002) 1255-1262
25. Nakanishi M., Goldstein J.L., and Brown M.S. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J Biol Chem 263 (1988) 8929-8937
26. Osborne T.F., Gil G., Goldstein J.L., and Brown M.S. Operator constitutive mutation of 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter abolishes protein binding to sterol regulatory element. J Biol Chem 263 (1988) 3380-3387
27. Shipman C.M., Croucher P.I., Russell R.G., Helfrich M.H., and Rogers M.J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58 (1998) 5294-5297
28. van de Donk N.W., Schotte D., Kamphuis M.M., van Marion A.M., van Kessel B., Bloem A.C., et al. Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin Cancer Res 9 (2003) 5735-5748
29. Gober H.J., Kistowska M., Angman L., Jeno P., Mori L., and De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197 (2003) 163-168
30. Roelofs A.J., Jauhiainen M., Mönkkönen H., Rogers M.J., Mönkkönen J., and Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144 (2009) 245-250
31. Mönkkönen H., Tormalehto S., Asunmaa K., Niemi R., Auriola S., Vepsalainen J., et al. Cellular uptake and metabolism of clodronate and its derivatives in Caco-2 cells: a possible correlation with bisphosphonate-induced gastrointestinal side-effects. Eur J Pharm Sci 19 (2003) 23-29
32. Crick D.C., Andres D.A., and Waechter C.J. Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun 237 (1997) 483-487
33. Edwards P.A., Ashby M.N., Spear D.H., Marrero P.F., Joly A., and Popjak G. Polyisoprenoid synthesis and metabolism. Biochem Soc Trans 20 (1992) 475-479
34. Ownby S.E., and Hohl R.J. Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis. Lipids 38 (2003) 751-759
35. Brown J.E., Neville-Webbe H., and Coleman R.E. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 11 (2004) 207-224
36. Senaratne S.G., Mansi J.L., and Colston K.W. The bisphosphonate zoledronic acid impairs Ras membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 86 (2002) 1479-1486
37. Oades G.M., Senaratne S.G., Clarke I.A., Kirby R.S., and Colston K.W. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170 (2003) 246-252
38. van Beek E., Lowik C., van der Pluijm G., and Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14 (1999) 722-729
39. Dunford J.E., Kwaasi A.A., Rogers M.J., Barnett B.L., Ebetino F.H., Russell R.G., et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 51 (2008) 2187-2195
40. Gibbs J.B., and Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37 (1997) 143-166
41. Hahn F.M., Xuan J.W., Chambers A.F., and Poulter C.D. Human isopentenyl diphosphate: dimethylallyl diphosphate isomerase: overproduction, purification, and characterization. Arch Biochem Biophys 332 (1996) 30-34
42. Zheng W., Sun F., Bartlam M., Li X., Li R., and Rao Z. The crystal structure of human isopentenyl diphosphate isomerase at 1.7 A resolution reveals its catalytic mechanism in isoprenoid biosynthesis. J Mol Biol 366 (2007) 1447-1458
43. Brown M.S., Faust J.R., Goldstein J.L., Kaneko I., and Endo A. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253 (1978) 1121-1128
44. Correll C.C., Ng L., and Edwards P.A. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 269 (1994) 17390-17393